Macrogenics is a biotechnology company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and other serious diseases
The company’s research and development efforts aim to harness the power of the immune system to fight tumors, utilizing advanced technologies to engineer molecules that can specifically target and modulate tumor-associated antigens. Macrogenics collaborates with various partners to advance its pipeline of proprietary and partnered programs, including therapies that are currently undergoing clinical trials, with the goal of providing new treatment options for patients with unmet medical needs.
A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures.
